MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1542/peds.2008-0313

Медицинская библиотека · Pediatrics · 2009

Determination of genetic predisposition to patent ductus arteriosus in preterm infants.

Dagle John M, Lepp Nathan T, Cooper Margaret E, Schaa Kendra L, Kelsey Keegan J P, Orr Kristin L, Caprau Diana, Zimmerman Cara R, Steffen Katherine M, Johnson Karen J, Marazita Mary L, Murray Jeffrey C

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to approximately 70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants.

METHODOLOGY: We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles.

RESULTS

P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 beta and tumor necrosis factor receptor-associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population.

CONCLUSIONS

Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.

Для цитирования: Dagle John M, Lepp Nathan T, Cooper Margaret E, Schaa Kendra L, Kelsey Keegan J P, Orr Kristin L, Caprau Diana, Zimmerman Cara R, Steffen Katherine M, Johnson Karen J, Marazita Mary L, Murray Jeffrey C. Determination of genetic predisposition to patent ductus arteriosus in preterm infants.. Pediatrics. 2009. DOI: 10.1542/peds.2008-0313.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.